Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DYNLRB2 antisense RNA 1 (DYNLRB2-AS1)
- Target
- DYNLRB2-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA
01
Overview
DYNLRB2-AS1 is a long non-coding RNA encoded on the antisense strand of the DYNLRB2 gene. It has been identified as one of the most upregulated lncRNAs in gemcitabine-resistant nasopharyngeal carcinoma cell lines. Functionally, it promotes cell proliferation and oncogenicity while inhibiting apoptosis. Mechanistically, DYNLRB2-AS1 binds to the DHX9 protein, preventing its ubiquitin-mediated degradation, which contributes to chemoresistance. These characteristics make it a potential biomarker for chemotherapy resistance in cancer but do not classify it as a canonical "drug target" like a receptor or enzyme.
- Other names
- DYNLRB2-AS1DYNLRB2 antisense RNA 1
02
Mechanism of action
Binds DHX9 protein, inhibits its ubiquitination/degradation, leading to increased cell proliferation and chemoresistance
03
Biological functions
Oncogenic regulatorPromotes cell proliferationInhibits apoptosisRegulates gemcitabine resistance
04
Disease associations
Cancer (especially nasopharyngeal carcinoma)Chemoresistance (gemcitabine resistance)
05
Safety considerations
Therapeutic targeting of lncRNAs is challenging; off-target effects and specificity are notable concerns in potential RNA-based therapies.
06
Interacting drugs
Gemcitabine
07
Biomarkers
Potential biomarker for gemcitabine resistance in nasopharyngeal carcinoma
Beyond the preview
Go deeper on DYNLRB2 antisense RNA 1 (DYNLRB2-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DYNLRB2 antisense RNA 1 (DYNLRB2-AS1).